Colchicine Use After Acute Coronary Syndrome: Evidence‑Based Recommendations

1. Guideline Recommendation and Evidence Grade

• The 2025 ACC/AHA guideline gives colchicine a Class IIb recommendation (may be reasonable) for reducing major adverse cardiovascular events (MACE) after an acute coronary syndrome (ACS). Strength: moderate recommendation based on mixed trial data. 1

2. Efficacy Evidence

2.1 Positive Trial (COLCOT)

• In the COLCOT randomized trial, initiating low‑dose colchicine (0.5 mg daily) 14 – 30 days after myocardial infarction reduced the composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent revascularisation by 32 % (hazard ratio 0.68). The benefit was driven mainly by a 74 % reduction in stroke (HR 0.26) and fewer hospitalisations for angina requiring revascularisation; there was no significant mortality reduction. Evidence level: high‑quality RCT. 1

2.2 Negative/Neutral Trial (COPS)

• The COPS trial started colchicine during the index ACS hospitalisation. The primary composite endpoint was not statistically different (P = 0.09), and non‑cardiovascular deaths were higher with colchicine (8 vs 1; P = 0.017), raising safety concerns for very early initiation. Evidence level: RCT with safety signal. 1

3. Safety Profile and Contraindications

3.1 General Safety

• Low‑dose colchicine (0.5‑0.6 mg daily) is reasonably safe after ACS when patients with severe renal impairment (creatinine clearance < 15 mL/min), severe hepatic disease, blood dyscrasias, or concurrent strong CYP3A4/P‑gp inhibitors are excluded. 1

3.2 Absolute Contraindications (FDA)

• Never use colchicine in patients with:
• Co‑administration with these inhibitors can cause life‑threatening toxicity even at therapeutic doses. 1

3.3 Drug‑Interaction Adjustments

• Moderate CYP3A4/P‑gp inhibitors (e.g., diltiazem, verapamil) require dose reduction of colchicine but are not absolute contraindications. 2

4. Dosing Recommendations

All dosing guidance is derived from the 2025 ACC/AHA guideline and supporting JACC evidence. 2

5. Timing of Initiation

• Initiate colchicine 14‑30 days after myocardial infarction rather than during the index hospitalisation. This timing aligns with the positive COLCOT results (median 14‑day delay) and avoids the mortality signal observed in the COPS trial with immediate initiation. 1

• Exception: For post‑MI pericarditis (incidence ≈ 0.1‑0.5 %), colchicine 0.5‑0.6 mg once or twice daily for 3 months is appropriate for symptom control. 2

6. Peri‑operative Management

• Discontinue colchicine ≥ 3 days before scheduled surgery (including coronary artery bypass grafting) if the patient is taking SGLT‑2 inhibitors (canagliflozin, dapagliflozin, empagliflozin).
• If the patient uses ertugliflozin, stop colchicine ≥ 4 days pre‑operatively to reduce ketoacidosis risk. 1

7. Clinical Decision Framework (When to Add Colchicine)

Prior to colchicine, ensure guideline‑directed medical therapy (high‑intensity statin, dual antiplatelet therapy, beta‑blocker, ACE‑inhibitor/ARB) is fully optimized. 1

Colchicine Therapy in Ischemic Heart Disease

Evidence for Efficacy

• The American College of Cardiology/American Heart Association gives colchicine a Class 2b recommendation for patients after acute coronary syndrome to reduce risk of major adverse cardiovascular events, with a 32% reduction in the composite outcome of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent coronary revascularization when colchicine was started within 30 days post-MI 3
• The American College of Cardiology/American Heart Association recommends colchicine for patients with ischemic heart disease, particularly after acute coronary syndrome or in chronic coronary disease, to reduce major adverse cardiovascular events, though it does not reduce mortality 3

Critical Safety Considerations

• The American College of Cardiology/American Heart Association recommends avoiding colchicine in patients with severe renal impairment (creatinine clearance <15 mL/min), severe hepatic impairment, blood dyscrasias, or concomitant use with P-glycoprotein and/or strong CYP3A4 inhibitors (cyclosporin, clarithromycin) 3
• The American Heart Association warns that the simvastatin-colchicine combination has resulted in 6 reported cases of myopathy, including one death from rhabdomyolysis and multiorgan failure, and recommends using rosuvastatin as the preferred statin when combining with colchicine 4

Practical Dosing Algorithm

• The American College of Cardiology/American Heart Association recommends a standard dose of 0.5 mg or 0.6 mg once daily for secondary prevention in chronic coronary disease or post-ACS, with dose adjustments required when on atorvastatin or simvastatin, or with renal impairment 3, 4
• The American College of Cardiology/American Heart Association recommends stopping colchicine ≥3 days prior to scheduled surgery if on canagliflozin, dapagliflozin, or empagliflozin (≥4 days for ertugliflozin) due to ketoacidosis risk with SGLT-2 inhibitors 3

Colchicine in Coronary Artery Disease and Heart Failure

Benefits of Colchicine in Coronary Artery Disease

• For chronic coronary disease (stable patients ≥6 months post-event), colchicine 0.5 mg daily reduces major adverse cardiovascular events by 31% (HR 0.69, 95% CI 0.57-0.83) 5
• This benefit is driven by reductions in myocardial infarction (24% reduction), stroke (52% reduction), and unstable angina requiring revascularization (39% reduction) 5
• The American College of Cardiology recommends colchicine for secondary prevention in chronic coronary disease 5

Critical Safety Considerations

• Simvastatin-colchicine combination has resulted in 6 reported cases of myopathy, with one progressing to rhabdomyolysis, multiorgan failure, and death 6, 7
• Both drugs independently cause myopathy, and coadministration produces synergistic muscle-related toxicity 7, 8
• If colchicine must be used with statins (for coronary disease, NOT heart failure), dose adjustments are mandatory: loading doses ≤0.6-1.2 mg and maintenance doses 0.3-0.6 mg daily 6, 9
• Rosuvastatin is the safest statin to combine with colchicine, as it doesn't interact with colchicine's metabolic pathways 6, 8
• In patients with renal impairment (common in heart failure), reduced colchicine doses are essential 6, 9